EDAP Announces Webcast and Conference Call of Second Quarter 2008 Results
Aug 05,2008
EDAP Announces Webcast and Conference Call of Second Quarter 2008 Results
EDAP Announces Webcast and Conference Call of Second Quarter 2008 Results
EDAP Announces Webcast and Conference Call of Second Quarter 2008 ResultsLYON, France, Aug 5, 2008 (PrimeNewswire via COMTEX News Network) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today details relating to its second quarter 2008 earnings announcement, which will take place on Thursday, August 21, 2008, before the opening of the market.
EDAP will hold a conference call on Thursday, August 21, 2008 at 8:30 a.m. ET to discuss the results. The dial-in numbers are 1-888-241-0558 for domestic callers and 1-647-427-3417 for international. The conference ID number for both is 59091975. A live Webcast of the conference call will be available online from the investor relations page of the Company's new corporate Website at www.edap-tms.com.
After the live Webcast, the call will remain available on EDAP's Website, www.edap-tms.com, through November 21, 2008. In addition, a telephonic replay of the call will be available until August 26, 2008. The replay dial-in numbers are 1-800-766-3146 for domestic callers and 1-402-220-7733 for international callers. Please use event ID number 59091975.
About EDAP TMS SA
EDAP TMS SA develops and markets Ablatherm, the most advanced and clinically proven choice for high-intensity focused ultrasound (HIFU) treatment of localized prostate cancer. HIFU treatment is shown to be a minimally invasive and effective treatment option with a low occurrence of side effects. Ablatherm-HIFU is generally recommended for patients with localized prostate cancer (stages T1-T2) who are not candidates for surgery or who prefer an alternative option, or for patients who failed radiotherapy treatment. Approved in Europe as a treatment for prostate cancer, Ablatherm-HIFU (High Intensity Focused Ultrasound) is currently undergoing evaluation in a multicenter U.S. Phase II/III clinical trial under an Investigational Device Exemption granted by the FDA. The Company also is developing this technology for the potential treatment of certain other types of tumors. EDAP TMS SA also produces and commercializes medical equipment for treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL). For more information on the company, please visit http://www.edap-tms.com, http://www.hifu-planet.com and http://www.pcaresearch.com or http://www.urotoday.com/HIFU.
This news release was distributed by PrimeNewswire, www.primenewswire.com
SOURCE: EDAP TMS S.A.
EDAP TMS SA Investor Relations / Legal Affairs Blandine Confort +33 4 72 15 31 72 bconfort@edap-tms.com
The Ruth Group Investors: R.J. Pellegrino 646-536-7009 rpellegrino@theruthgroup.com
© Copyright 2008 PrimeNewswire, Inc. All rights reserved.
News Provided by COMTEX
EDAP will hold a conference call on Thursday, August 21, 2008 at 8:30 a.m. ET to discuss the results. The dial-in numbers are 1-888-241-0558 for domestic callers and 1-647-427-3417 for international. The conference ID number for both is 59091975. A live Webcast of the conference call will be available online from the investor relations page of the Company's new corporate Website at www.edap-tms.com.
After the live Webcast, the call will remain available on EDAP's Website, www.edap-tms.com, through November 21, 2008. In addition, a telephonic replay of the call will be available until August 26, 2008. The replay dial-in numbers are 1-800-766-3146 for domestic callers and 1-402-220-7733 for international callers. Please use event ID number 59091975.
About EDAP TMS SA
EDAP TMS SA develops and markets Ablatherm, the most advanced and clinically proven choice for high-intensity focused ultrasound (HIFU) treatment of localized prostate cancer. HIFU treatment is shown to be a minimally invasive and effective treatment option with a low occurrence of side effects. Ablatherm-HIFU is generally recommended for patients with localized prostate cancer (stages T1-T2) who are not candidates for surgery or who prefer an alternative option, or for patients who failed radiotherapy treatment. Approved in Europe as a treatment for prostate cancer, Ablatherm-HIFU (High Intensity Focused Ultrasound) is currently undergoing evaluation in a multicenter U.S. Phase II/III clinical trial under an Investigational Device Exemption granted by the FDA. The Company also is developing this technology for the potential treatment of certain other types of tumors. EDAP TMS SA also produces and commercializes medical equipment for treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL). For more information on the company, please visit http://www.edap-tms.com, http://www.hifu-planet.com and http://www.pcaresearch.com or http://www.urotoday.com/HIFU.
This news release was distributed by PrimeNewswire, www.primenewswire.com
SOURCE: EDAP TMS S.A.
EDAP TMS SA Investor Relations / Legal Affairs Blandine Confort +33 4 72 15 31 72 bconfort@edap-tms.com
The Ruth Group Investors: R.J. Pellegrino 646-536-7009 rpellegrino@theruthgroup.com
© Copyright 2008 PrimeNewswire, Inc. All rights reserved.
News Provided by COMTEX